ClinicalTrials.gg
CompletedNCT02123134Updated Feb 17, 2020Results posted

Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age

A Phase 3 interventional study of ATX-101 and Placebo in Moderate to Severe Convexity of Submental Fat, Safety and Efficacy, sponsored by Kythera Biopharmaceuticals. Completed at 6 sites in United States. Open to participants aged 65 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-17.

Sponsored by Kythera Biopharmaceuticals (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
65 Years to 75 Years
Sex
All
01

Study summary

The objectives of this study are to explore the safety and efficacy of subcutaneous injections of Deoxycholic Acid relative to placebo, in the submental area of participants who are 65 to 75 years old.

02

Conditions studied

  • Moderate to Severe Convexity of Submental Fat
  • Safety
  • Efficacy
03

In context

Lead sponsor

Kythera Biopharmaceuticals is the lead sponsor of 23 studies on the registry; none are open to participants now.

First submitted before Kythera Biopharmaceuticals became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females, 65 to 75 years of age
  • Stable Body Weight
  • Dissatisfaction with the submental area expressed by participants
  • Acceptable volume of submental fat graded by clinician
  • of ≤40.0 kg/m\^2
  • Signed (ICF)
  • SMF rating of 2 or 3 by clinician and patient

Exclusion criteria

Exclusion Criteria:

  • No prior intervention for submental fat (SMF) (eg liposuction, surgery or lipolytic agents)
  • Absence of health problems
  • Anatomical features for which reduction in SMF may result in aesthetically unacceptable outcome, judged by clinician
  • History of trauma associated with the chin or neck areas that in the judgment of the investigator may affect evaluation of safety or efficacy
  • of ≥40.0 kg/m\^2
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
55 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo administered in 0.2 mL subcutaneous (SC) injections, up to 10 milliliters (mL) per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.

    Drug: Placebo

  • Experimental
    ATX-101 deoxycholic acid injection

    Participants received deoxycholic acid 2 mg/cm\^2 administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.

    Drug: ATX-101

Interventions

  • Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.

    Also known as: deoxycholic acid

  • DrugPlacebo

    Phosphate buffered saline placebo for injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Both the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) Assessments

    The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst).

    Time frame: Baseline and up to Week 32 (12 weeks after last treatment)

  2. Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Both the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) Assessments

    The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst).

    Time frame: Baseline and up to Week 32 (12 weeks after last treatment)

  3. Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)

    The investigator evaluated the participant's chin and neck area using the CR-SMFRS 5-point scale where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst).

    Time frame: Baseline and up to Week 32 (12 weeks after last treatment)

  4. Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)

    The investigator evaluated the participant's chin and neck area using the CR-SMFRS 5-point scale where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst).

    Time frame: Baseline and up to Week 32 (12 weeks after last treatment)

  5. Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Patient-Reported Submental Fat Rating Scale (PR-SMFRS)

    The participant evaluated their chin and neck area using the PR-SMFRS 5-point scale where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst).

    Time frame: Baseline and up to Week 32 (12 weeks after last treatment)

  6. Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Patient-Reported Submental Fat Rating Scale (PR-SMFRS)

    The participant evaluated their chin and neck area using the PR-SMFRS 5-point scale where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst).

    Time frame: Baseline and up to Week 32 (12 weeks after last treatment)

  7. Change From Baseline in Submental Skin Laxity Grade Scale (SMSLG)

    The SMSLG is an integration of three features: skin wrinkling, adherence to underlying neck structures (bone and muscle) and redundancy (horizontal and vertical folds). Each grade (1=none, 2=mild, 3=moderate and 4=severe) defines the maximal allowed limit for skin wrinkling, adherence to underlying structures and redundancy.

    Time frame: Baseline and up to Week 32 (12 weeks after last treatment)

07

Results

Posted Feb 17, 2020

Participant flow

A total of 55 subjects were randomized to either ATX-101 or placebo at a ratio of 1:1. A total of 28 subjects received ATX-101 and 26 subjects received placebo; 1 subject (803-003) was randomized to placebo but was not treated with placebo.

Participant flow — Overall Study
MilestoneATX-101 (Deoxycholic Acid) InjectionPlacebo
Started2827
Completed2524
Not completed33
Withdrew: Withdrawal of consent32
Withdrew: Administrative decision01

Outcome measures

PrimaryPercentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Both the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) Assessments

The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst).

Time frame:
Baseline and up to Week 32 (12 weeks after last treatment)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Both the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) Assessments
percentage of participantsATX-101 (Deoxycholic Acid) InjectionPlacebo
Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Both the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) Assessments68.0 (49.7 to 86.3)25.0 (7.7 to 42.3)
PrimaryPercentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Both the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) Assessments

The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst).

Time frame:
Baseline and up to Week 32 (12 weeks after last treatment)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Both the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) Assessments
percentage of participantsATX-101 (Deoxycholic Acid) InjectionPlacebo
Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Both the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) Assessments8.0 (0.0 to 18.6)4.2 (0.0 to 12.2)
PrimaryPercentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)

The investigator evaluated the participant's chin and neck area using the CR-SMFRS 5-point scale where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst).

Time frame:
Baseline and up to Week 32 (12 weeks after last treatment)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)
percentage of participantsATX-101 (Deoxycholic Acid) InjectionPlacebo
Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)84.0 (69.6 to 98.4)41.7 (21.9 to 61.4)
PrimaryPercentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)

The investigator evaluated the participant's chin and neck area using the CR-SMFRS 5-point scale where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst).

Time frame:
Baseline and up to Week 32 (12 weeks after last treatment)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)
percentage of participantsATX-101 (Deoxycholic Acid) InjectionPlacebo
Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)60.0 (40.8 to 79.2)12.5 (0.0 to 25.7)
PrimaryPercentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Patient-Reported Submental Fat Rating Scale (PR-SMFRS)

The participant evaluated their chin and neck area using the PR-SMFRS 5-point scale where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst).

Time frame:
Baseline and up to Week 32 (12 weeks after last treatment)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Patient-Reported Submental Fat Rating Scale (PR-SMFRS)
percentage of participantsATX-101 (Deoxycholic Acid) InjectionPlacebo
Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Patient-Reported Submental Fat Rating Scale (PR-SMFRS)80.0 (64.3 to 95.7)45.8 (25.9 to 65.8)
PrimaryPercentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Patient-Reported Submental Fat Rating Scale (PR-SMFRS)

The participant evaluated their chin and neck area using the PR-SMFRS 5-point scale where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst).

Time frame:
Baseline and up to Week 32 (12 weeks after last treatment)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Patient-Reported Submental Fat Rating Scale (PR-SMFRS)
percentage of participantsATX-101 (Deoxycholic Acid) InjectionPlacebo
Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Patient-Reported Submental Fat Rating Scale (PR-SMFRS)20.0 (4.3 to 35.7)20.8 (4.6 to 37.1)
PrimaryChange From Baseline in Submental Skin Laxity Grade Scale (SMSLG)

The SMSLG is an integration of three features: skin wrinkling, adherence to underlying neck structures (bone and muscle) and redundancy (horizontal and vertical folds). Each grade (1=none, 2=mild, 3=moderate and 4=severe) defines the maximal allowed limit for skin wrinkling, adherence to underlying structures and redundancy.

Time frame:
Baseline and up to Week 32 (12 weeks after last treatment)
Reported as:
Mean · scores on a scale
Change From Baseline in Submental Skin Laxity Grade Scale (SMSLG)
scores on a scaleATX-101 (Deoxycholic Acid) InjectionPlacebo
Change From Baseline in Submental Skin Laxity Grade Scale (SMSLG)-0.5 ± 0.65-0.1 ± 0.45

Adverse events

Collected over Up to 32 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ATX-101 (Deoxycholic Acid) Injection0/28 (0%)0/28 (0%)28/28 (100%)
Placebo0/26 (0%)1/26 (3.8%)23/26 (88.5%)
Most frequent serious events
Most frequent serious events
EventATX-101 (Deoxycholic Acid) InjectionPlacebo
UrosepsisInfections and infestations0/281/26
Most frequent other events
Showing 10 of 13
Most frequent other events
EventATX-101 (Deoxycholic Acid) InjectionPlacebo
Injection site bruisingGeneral disorders20/2815/26
Injection site painGeneral disorders20/283/26
Injection site swellingGeneral disorders17/2815/26
Injection site anaesthesiaGeneral disorders14/280/26
Injection site noduleGeneral disorders8/283/26
Injection site oedemaGeneral disorders5/280/26
Injection site erythemaGeneral disorders4/283/26
Injection site indurationGeneral disorders4/280/26
NasopharyngitisInfections and infestations0/282/26
HeadacheNervous system disorders1/282/26

Baseline characteristics

Age, Continuous
Age, Continuous(years)ATX-101 (Deoxycholic Acid) InjectionPlaceboTotal
Mean68.1 ± 2.7667.7 ± 2.3067.9 ± 2.53
Age, Customized
Age, Customized(Participants)ATX-101 (Deoxycholic Acid) InjectionPlaceboTotal
65-69 years222244
70-75 years6511
Sex: Female, Male
Sex: Female, Male(Participants)ATX-101 (Deoxycholic Acid) InjectionPlaceboTotal
Female232144
Male5611
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ATX-101 (Deoxycholic Acid) InjectionPlaceboTotal
Hispanic or Latino123
Not Hispanic or Latino272552
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ATX-101 (Deoxycholic Acid) InjectionPlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American224
White252550
More than one race101
Unknown or Not Reported000
Fitzpatrick Skin Type
Fitzpatrick Skin Type(Participants)ATX-101 (Deoxycholic Acid) InjectionPlaceboTotal
I011
II151025
III71219
IV213
V325
VI112
Weight
Weight(kg)ATX-101 (Deoxycholic Acid) InjectionPlaceboTotal
Mean77.44 ± 14.17084.10 ± 14.07080.71 ± 14.388
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)ATX-101 (Deoxycholic Acid) InjectionPlaceboTotal
Mean29.27 ± 4.20730.72 ± 4.69429.98 ± 4.471

4 further baseline measures are reported on the registry.

08

Study locations

6 sites
  • Birmingham, Alabama 35205, United States
  • Los Angeles, California 90036, United States
  • Bradenton, Florida 34209, United States
  • Metairie, Louisiana 70006, United States
  • White Plains, New York 10604, United States
  • Cincinnati, Ohio 45255, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Aug 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2020, 4 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2014
First posted
Apr 25, 2014
Start
Apr 2014
Primary completionActual
Aug 2015
CompletionActual
Sep 2015
Results first posted
Feb 17, 2020
Last update
Feb 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02123134
Responsible party
Sponsor
First posted
Apr 25, 2014
Start date
Apr 2014
Primary completion
Aug 2015
Completion
Sep 2015
Results posted
Feb 17, 2020
Last update
Feb 17, 2020

Study contacts

Frederick Beddingfield, III, MD, PhD
study director · Sponsor GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: APIM-containing Peptide ATX-101

Start the discussion